miR-125b suppresses oral oncogenicity by targeting the anti-oxidative gene PRXL2A.

Redox Biol · 2019 · PMC6383183 · PMID 30785086

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Since the OSCC patients that were found to have strong PRXL2A expression also showed a trend towards worse survival [ 6 ], anti-PRXL2A strategies may be a feasible approach to improve OSCC therapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.